Table 4 Effect of baseline characteristics on survival measures in patients with de novo del(17p) (n = 310)

From: Natural history of multiple myeloma with de novo del(17p)

Independent variable

Progression-free survival (PFS)

Overall survival (OS)

p-value for univariable analysis

HR (95% CI) for multivariable analysis

p-value for multivariable analysis

p-value for univariable analysis

HR (95% CI) for multivariable analysis

p-value for multivariable analysis

Age ≥65 vs. <65 years (147 vs. 163)

0.714

NI

–

0.010

1.40 (0.96–2.04)

0.079

Creatinine >2 vs. ≤2 mg/dL (52 vs. 231)

0.027

1.18 (0.66–2.00)

0.561

0.072

0.86 (0.49–1.47)

0.600

Bone marrow PCs ≥50% vs. <50% (164 vs. 140)

0.110

NI

–

0.536

NI

–

ISS III vs. I/II stage (93 vs. 154)

<0.001

1.89 (1.31–2.71)

<0.001

<0.001

2.08 (1.42–3.04)

<0.001

Elevated vs. normal LDH (49 vs. 157)

0.001

1.72 (1.13–2.53)

0.012

0.003

1.83 (1.16–2.80)

0.009

High-risk translocation vs. no high-risk translocation (75 vs. 235)

0.001

1.61 (1.10–2.32)

0.015

<0.001

1.53 (1.01–2.27)

0.044

Monosomy 13 vs. no monosomy 13 (163 vs. 147)

0.020

1.08 (0.75–1.57)

0.672

0.024

1.04 (0.63–1.72)

0.885

HRD vs. no HRD (112 vs. 198)

<0.001

0.88 (0.54–1.42)

0.614

0.038

0.79 (0.52–1.20)

0.277

High PC proliferative rate vs. low proliferative rate (42 vs. 98)

<0.001

1.56 (0.93–2.60)

0.090

0.042

0.92 (0.52–1.63)

0.788

PI-containing induction vs other induction therapy (219 vs. 89)

0.935

NI

–

0.472

NI

–

Diagnosis upto 2012 vs. later (173 vs. 137)

<0.001

0.52 (0.36–0.75)

<0.001

0.011

0.76 (0.47–1.19)

0.236

Percentage of PCs with del(17p)

≥20% vs. <20% (224 vs. 36)

0.074

1.85 (0.96–4.13)

0.068

<0.001

1.07 (0.38–4.46)

0.916

≥30% vs. <30% (207 vs. 53)

0.057

1.91 (1.12–3.50)

0.015

<0.001

1.36 (0.65–3.34)

0.441

≥40% vs. <40% (193 vs. 67)

0.012

1.85 (1.15–3.12)

0.009

0.001

1.17 (0.60–2.49)

0.662

≥50% vs. <50% (170 vs. 90)

0.025

1.45 (0.96–2.26)

0.079

0.011

1.09 (0.62–2.03)

0.769

≥60% vs. <60% (153 vs. 107)

0.050

1.28 (0.89–1.88)

0.184

<0.001

1.18 (0.67–2.11)

0.570

  1. The final multivariable model included 174 patients for PFS and 191 patients for OS for whom the parameters were available
  2. Hyperdiploidy was defined as presence of trisomy involving ≥2 odd numbered chromosomes; the results were similar when presence of any trisomy/tetrasomy was used instead of HRD
  3. HR hazard ratio, HRD hyperdiploidy, ISS international staging system, LDH lactate dehydrogenase, NI not included in analysis, PC plasma cell, and PI proteasome inhibitor.
  4. The values given in bold represent P-values <0.05, which are considered statistically significant
Back to article page